...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: 6%

If management goes with the royalty revenue stream option, all monies go to ZCC.

If management goes with the sale of the ZEN-3694 option, all monies go to ZCC.

No monies go to RVX. RVX is a separate company.

 

Koo

Share
New Message
Please login to post a reply